Program Information
Improving Linac QA with TG142 and Beyond
E Klein1*, J O'Daniel2*, B Heintz3*, (1) Washington University, Saint Louis, MO, (2) Duke University Medical Center, Durham, NC, (3) Texas Oncology, PA, Southlake, TX
Presentations
MO-A-BRD-0 (Monday, March 9, 2015) 7:30 AM - 9:30 AM Room: Ballroom D
Six years after publication, full clinical implementation of the AAPM TG-142 report on accelerator quality assurance remains challenging. First, the choice of methodologies and vendor tools to satisfy TG-142 requirements is critical to successful implementation. There are many options for hardware and software programs that may or may not be ideal for a particular clinic’s needs. Second, there are many QA tests not covered in TG-142 (i.e. arc therapy techniques) that need the physicist’s attention. Third, to achieve a clinic-specific QA process that is both effective and efficient, it is critical to determine the relative importance of each test. Failure mode and effect analysis (in the vein of TG-100) allows for a quantitative comparison of each test’s clinical impact.
Learning Objectives:
1. To learn about the current vendor tools available for TG-142 testing and to understand the pros and cons of each tool
2. To understand what is still missing from TG-142 and how to account for these tests in clinical practice
3. To quantify the clinical impact and relative importance of QA tests in TG-142 via FMEA analysis
Handouts
- 97-25837-352470-109883-463807386.pdf (E Klein)
- 97-25838-352470-109884-1226979764.pdf (J O'Daniel)
- 97-25839-352470-109885-1962369027.pdf (B Heintz)
Contact Email: